March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
November 2025 in “Discover Food” Catechins-rich tea extract may help reduce hair loss and promote hair growth.
November 2025 in “Journal of Pioneering Medical Science” Dietary interventions improved hair density and reduced dandruff by balancing scalp microbiota and reducing inflammation.
November 2025 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” A combined treatment with microneedling and vitamin D3 led to complete hair regrowth in a woman with stubborn patch alopecia areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
October 2025 in “International Journal of Cell and Biomedical Science” hUC-MSC secretome can help regrow hair in cases of hair loss.
Baricitinib effectively regrows hair in severe alopecia areata cases.
October 2025 in “Iraqi postgraduate medical journal” Combining laser treatment with steroid cream is more effective for alopecia areata than using the cream alone.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
March 2024 in “Intisari Sains Medis” Low free thyroxine (FT4) is common in young lupus patients and needs quick diagnosis and treatment.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
December 2023 in “International journal of multidisciplinary research and analysis” SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.
October 2023 in “Benha Journal of Applied Sciences” PPAR-γ may be a key target for treating alopecia areata and other skin conditions.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
October 2022 in “The Egyptian Journal of Hospital Medicine” Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.
January 2022 in “International journal of zoology and animal biology” Dogs with dermatomyositis, especially Collies and Shetland Sheepdogs, need better treatments for their skin and muscle inflammation.
April 2021 in “Journal of Investigative Dermatology” Photobiomodulation therapy may help treat hair loss in people with darker skin, but more research is needed.
January 2021 in “Benha Journal of Applied Sciences” Prolactin levels and gene polymorphism are not linked to vitiligo severity but are related to BMI.
Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.
Ajwain seed extract improved skin healing and hair growth in a mouse skin irritation model.
July 2018 in “Elsevier eBooks” Discoid Lupus Erythematosus often causes scarring hair loss, is influenced by genetics and environment, and requires early treatment to prevent worsening.
June 2018 in “Biomedical Journal of Scientific & Technical Research” Cells can change to help heal wounds better.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
February 2018 in “Trends in Immunology” Skin bacteria can help wound healing by activating certain immune cells.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.